Development of a men's Preference for Testosterone Replacement Therapy (P-TRT) instrument

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 631-641

  Szeinbach, Sheryl L ^a   Seoane Vazquez, Enrique ^b   Summers, Kent H ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c Endo Health Solutions   (United States)

Author keywords

Hormones; Hypogonadism; Outcome assessment; Patient preference; Testosterone

Indexed keywords

TESTOSTERONE;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; ATTITUDE TO HEALTH; COGNITION; COMPUTER PROGRAM; DRUG USE; HEALTH CARE QUALITY; HUMAN; HYPOGONADISM; INFORMED CONSENT; LIBIDO; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MEN'S HEALTH; PATIENT COMPLIANCE; QUALITATIVE ANALYSIS; TELEPHONE INTERVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 84886039191     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S35840     Document Type: Article

References (31)

1. Araujo AB, Wittert GA. Endocrinology of the aging male. Best Pract Res Clin Endocrinol Metab. 2011;25(2):303-319.
2. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study. J Clin Endocrinol Metab. 2004;89(12):5920-5926.
3. Wu FC, Tajar A, Beynon JM, et al; EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123-135.
4. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11): 4241-4247.
5. Bhasin S, Basaria S. Diagnosis and treatment of hypogonadism is men. Best Pract Res Clin Endocrinol Metab. 2011;25(2):251-270.
6. Hong BS, Ahn TY. Recent trends in the treatment of testosterone deficiency syndrome. Int J Urol. 2007;14(11):981-985.
7. Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl. 2006;27(2):135-137.
8. Bagatell CJ, Bremner WJ. Androgens in men-uses and abuses. N Engl J Med. 1996;334(11):707-715.
9. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335-4343.
10. Hall SA, Esche GR, Araujo AB, et al. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J Clin Endocrinol Metab. 2008;93(10):3870-3877.
11. Morales A. Andropause (or symptomatic late-onset hypogonadism): facts, fiction and controversies. Aging Male. 2004;7(4):297-303.
12. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87(2):589-598.
13. Travison TG, Araujo AB, O'Donnell AB, et al. A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Metab. 2007;92(1):196-202.
14. Tan RS, Cluberson JW. An integrative review on current evidence of testosterone replacement therapy for the andropause. Maturitas. 2003; 45(1):15-27.
15. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6): 2536-2559.
16. Flynn TN. Valuing citizen and patient preferences in health: recent development in three types of best-worst scaling. Expert Rev Pharmacoeconomics Outcomes Res. 2010;10(3):259-267.
17. Johansson G, Stallberg B, Tornling G, et al. Asthma treatment preference study-a conjoint analysis of preferred drug treatments. Chest. 2004;125(3):916-923.
18. Harpe SE, Szeinbach SL, Caswell RJ, et al. The relative importance of health related quality of life and prescription insurance coverage in the decision to pharmacologically manage symptoms of overactive bladder. J Urology. 2007;178(6):2532-2536.
19. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther. 2004;26(9):1498-1505.
20. Fennell C, Sartorius G, Ly LP, et al. Randomized cross-over clinical trial of injectable vs implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men. Clin Endocrinol. 2010;73(1):102-109.
21. Rhoden EL, Morgentaler A. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice. J Sex Med. 2010;7(1):277-283.
22. Center for Drug Evaluation and Research. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Rockville, MD: US Food and Drug Administration; 2009.
23. Glaser BG. The future of grounded theory. Qual Health Res. 1999;9(6): 836-845.
24. Victorson DE, Anton S, Hamilton A, et al. A conceptual model of the experience of dyspnea and functional limitations in chronic obstructive pulmonary disease. Value Health. 2009;12(6):1018-1025.
25. Budych K, Helms TM, Schultz C. How do patients with rare disease experience the medical encounter? Exploring role behavior and its impact on patient-physician interaction. Health Policy. 2012;105(2-3):154-164.
26. Strauss A, Corbin J. Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory. 2nd ed. Thousand Oaks, CA: Sage; 1998.
27. Goff SL, Mazor KM, Meterko V, et al. Patients' beliefs and preferences regarding doctors' medication recommendations. J Gen Intern Med. 2007;23(3):236-241.
28. Justicia JL, Baro E, Cardona V, et al. Development of a questionnaire to assess patient satisfaction with allergen-specific immunotherapy in adults: item generation, item reduction, and preliminary validation. Patient Prefer Adherence. 2011;5:239-250.
29. Solky BA, Phillips K, Christenson LJ, et al. Patient preferences for facial sunscreens: a split-face, randomized, blinded trial. J Am Acad Dermatol. 2007;57(1):67-72.
30. Eton DT, Shevrin DH, Beaumont J, et al. Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. Value Health. 2010;13(5):613-623.
31. Giagulli VA, Triggiani V, Corona G, et al. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: Focus on new formulations. Curr Pharm Des. 2011;17(15): 1500-1511.